Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
Tesla Launches New Model Y Variant in the US Starting at $41,990 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers 
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations 
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI 
HOUSTON, May 31, 2017 -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that Rick Fair, President and CEO, is scheduled to present a corporate overview at the Jefferies 2017 Global Healthcare Conference on Wednesday, June 7 at 2:00 p.m. EDT in New York, NY.
A live webcast of the presentation may be accessed from the News & Events section of the Bellicum website. An archived version of the webcast will be available for replay for at least two weeks following the event.
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR T and TCR cell therapies. More information can be found at www.bellicum.com.
Investors: Bellicum Pharmaceuticals Alan Musso, CFO 832-384-1116 [email protected] Media: BMC Communications Brad Miles 646-513-3125 [email protected]
